

10077910/070889

JC10 Rec'd PCT/PTG 06 MAR 2002

211A 3160 PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

MINORU TAKEBE

International Application No.:  
PCT/JP01/05944

International Filing Date: July 9, 2001

For: ANTI-OBESITY MATERIAL

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231  
Box: Patent Application

Dear Sir:

Please amend the above-identified application, which is now entering the U.S.  
National Stage pursuant to 35 U.S.C. Section 371, as follows:

**IN THE CLAIMS:**

Please amend claim 7 as follows:

7) (amended) The anti-obesity material according to any one of claims 1 through 4,  
characterized in that said anti-obesity material is formed into an oral supplement.

Please add new claims 8 and 9 as follows:

--8) The anti-obesity material according to claim 5, characterized in that said anti-obesity  
material is formed into an oral supplement.

9) The anti-obesity material according claim 6, characterized in that said anti-  
obesity material is formed into an oral supplement.--

REMARKS

Applicant respectfully submits that the above amendments to the claims are only for the purpose of rewriting claims so that they comply with 37 CFR 1.75, and no new matter is introduced via the amendment.

Accordingly, it is respectfully requested that this preliminary amendment be entered and the case be favorably considered.

Please charge any additional costs incurred by way of this amendment to Koda and Androlia Deposit Account No. 11-1445.

Respectfully submitted,

KODA & ANDROLIA

2029 Century Park East  
Suite 3850  
Los Angeles, CA 90067  
(310) 277-1391  
(310) 277-4118 (fax)

By: 

H. Henry Koda

Reg. No. 27,729

International Application No. PCT/JP01/05944

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS:**

Claim 7 has been amended as follows:

7) (amended) The anti-obesity material according to any one of claims 1 through [6] 4, characterized in that said anti-obesity material is formed into an oral supplement.

New Claims 8 and 9 have been added as follows:

--8) The anti-obesity material according to claim 5, characterized in that said anti-obesity material is formed into an oral supplement.

9) The anti-obesity material according claim 6, characterized in that said anti-obesity material is formed into an oral supplement.--